U.S. District Chief Judge Joseph Farnan Jr.'s decision to invalidate a patent on a long-lasting narcotic may ultimately cost drugmaker Purdue Frederick Co. as much as $600 million in worldwide sales, experts say. In a decision released May 7, Farnan in Wilmington concluded Purdue Frederick's patent on treating pain with a slow-release oral dose does not meet legal requirements in its written description to be valid.
May 18, 1999 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
U.S. District Chief Judge Joseph Farnan Jr.’s decision to invalidate a patent on a long-lasting narcotic may ultimately cost drugmaker Purdue Frederick Co. as much as $600 million in worldwide sales, experts say.
In a decision released May 7, Farnan in Wilmington concluded Purdue Frederick’s patent on treating pain with a slow-release oral dose does not meet legal requirements in its written description to be valid.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
